

The Future of UBI

 **Bringing the universal power of biosensors into the hands of those who need it**

©Copyright Universal Biosensors 2021. Private and confidential.



Universal Biosensors

Important Disclaimer

Presentation

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person.

Company

Neither the Company, nor its officers or advisors or any other person warrants the accuracy of the analysis herein or guarantees the investment performance of the Company. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes.

Statements

The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of the United States Exchange Act. Forward-looking statements in this presentation include statements regarding our expectations, beliefs, hopes, intentions or strategies.

All forward-looking statements included in this presentation are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations.

Risk

The Company is subject to a number of risks. For a summary of key risks, refer to the Company's most recent Form 10-K filed with the United States Securities and Exchange Commission and the Australian Securities Exchange.

Securities

Under applicable United States securities laws all of the shares of our common stock are "restricted securities" as that term is defined in Rule 144 under the Securities Act of 1933, as amended. Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.

Bringing the universal power of biosensors into the hands of those who need it



Universal Biosensors

Universal Biosensors (UBI)

UBI is a biosensor company and **world leader** in electrochemical cell technology with a long **history of innovation** and establishing **global partnerships**.

The biosensor market is estimated at AUD \$40 billion. Point of Care diagnostics and screening are among the key reasons for the overall increase in global demand for biosensors.

Advancements in biosensor technology and its applications include increased detection limits and miniaturization.

UBI's biosensor technology platform has been used to deliver more than **10 billion diagnostic tests** to patients worldwide generating billions of dollars in sales.

Bringing the universal power of biosensors into the hands of those who need it

SIEMENS

Johnson & Johnson



Universal Biosensors

UBI Products Current & Future

- Oenology
- Veterinary Diabetes
- Coagulation
- New Technologies



Sentia™

Sentia delivers **medical grade** biosensor technology to the wine industry.

Products include Free SO₂ testing (launch Feb 21), Glucose, Fructose and Malic Acid (launch during 2021) and Acetic and Total Acid (launch during 2022).

Sentia delivers testing specificity and sensitivity, **significant cost savings** and productivity gains to the wine industry.



Bringing the universal power of biosensors into the hands of those who need it

Sentia Competitive Advantage



01.

Fast

On the spot
results within
1 min

02.

Accurate

Improved
accuracy

03.

Portable

Genuine
'at barrel'
testing

04.

Efficient

Improve
processing
efficiency &
associated
costs

05.

Quality

In-built
quality
control
checks for
each test

06.

Easy

No reagents
Automatically
calibrated




SENTIA

Bringing the universal power of biosensors into the hands of those who need it

Sentia Competitive Advantage

| | Sentia | Aeration Oxidation | Thermo Gallery | Spectro- photometer | External Testing |
|--------------------------|--|-------------------------------|--------------------------------|--------------------------------|-----------------------------|
| Cost ¹ | \$1,950 / \$3.50 | \$1,000 / \$0.60 | \$75,000 / \$1 | \$4,000 / \$3 | \$35 |
| Labour cost ² | \$0.60 | \$12.00 | \$6.00 | \$12.00 | NA |
| Usability | Anyone | Wine / Lab staff | Lab staff | Wine / Lab staff | NA |
| Time | 1 min | 20 mins | 10 mins | 20 mins | 2+ days |
| Accuracy | Calibrated to Gold Standard | Operator dependent | Gold Standard | Operator dependent | Operator dependent |
| Data | Automatically stored to upload | Manual | Automatically stored to upload | Available on some models | Results provided |
| Competitive Advantage | Time, Cost, Accuracy, Simplicity, Portability, Quality | | | | |



Bringing the universal power of biosensors into the hands of those who need it

1. Device / consumables
 2. Calculation based on \$35ph
 All calculations are estimated and Australian dollars

Sentia Global Distribution

Sentia

- Launch Feb 2021.
- Distribution agreements in place for **Australia** and **USA**.
- Additional distribution agreements for rest of world expected during H1 2021.



Bringing the universal power of biosensors into the hands of those who need it

Sentia Global Market

| World Wide Market | | | | |
|--------------------------|------------------|-------------------|-------------------|--------------------|
| Number of Tests | ANZ | USA | RoW | Total |
| Free SO ₂ | 1,329,560 | 4,433,985 | 15,660,000 | 21,423,545 |
| Malic Acid | 930,692 | 3,103,789 | 10,962,000 | 14,996,481 |
| Glucose & Fructose | 2,127,296 | 7,094,376 | 25,056,000 | 34,277,672 |
| Total Acid | 664,780 | 2,216,992 | 7,830,000 | 10,711,772 |
| Acetic Acid | 1,329,560 | 4,433,985 | 15,660,000 | 21,423,545 |
| Total Tests | 6,381,888 | 21,283,127 | 75,168,000 | 102,833,015 |
| Total Devices | 2,311 | 7,929 | 50,100 | 60,340 |



All calculations are estimated and Australian dollars

Bringing the universal power of biosensors into the hands of those who need it

Sentia Global Market


| World Wide Market | | | | |
|----------------------|-------------------|--------------------|--------------------|--------------------|
| \$AUD | ANZ | USA | RoW | Total |
| FSO ₂ | 4,653,460 | 22,169,923 | 78,300,000 | 105,123,383 |
| Malic Acid | 7,445,536 | 35,471,876 | 125,280,000 | 168,197,412 |
| Glucose & Fructose | 7,445,536 | 35,471,876 | 125,280,000 | 168,197,412 |
| Total Acid | 3,988,680 | 13,301,952 | 46,980,000 | 64,270,632 |
| Acetic Acid | 10,636,480 | 35,471,880 | 125,280,000 | 171,388,360 |
| Total Tests | 34,169,692 | 141,887,507 | 501,120,000 | 677,177,199 |
| Total Devices | 4,044,250 | 25,485,906 | 139,564,286 | 169,094,442 |
| Total Revenue | 38,213,942 | 167,373,413 | 640,684,286 | 846,271,641 |

All calculations are estimated and Australian dollars



Bringing the universal power of biosensors into the hands of those who need it

Sentia Future Products



Bringing the universal power of biosensors into the hands of those who need it

Veterinary Diabetes

UBI signed a deal with LifeScan for the global rights to develop and commercialise a Vet blood glucose strip and meter.

Diabetes is a common disease in cats and dogs. It is caused by a deficiency of insulin. Treatment includes daily insulin injections as well as monitoring the pet's condition throughout the day.

Blood glucose levels should be checked twice a day at home and at a veterinary hospital every two to three months. This involves a day in a vet hospital where blood glucose curves are generated. Nearly all vet practices will have at least one point of care blood glucose monitoring device.



Vet Competitive Advantage

| | UBI Vet Product | AlphaTRAK 2 | CentriVet GK |
|--------------------------|---|---------------|---------------|
| Sample Size (µL) | 0.4 | 0.3 | 0.8 |
| Test Time (minutes) | 1 | 1 | 1 |
| Professional or Home Use | Both | Both | Both |
| Easy Data Download | Y | N | N |
| Test Capacity | 500 | 250 | 450 |
| Connectivity | Y | N | N |
| Cost ¹ | Competitive, Better Value | \$65 / \$1.30 | \$55 / \$0.82 |
| Competitive Advantage | Connectivity, Data Download Simplicity, Test Capacity, Cost | | |

1. Device / consumable
All prices are estimated and Australian dollars

Bringing the universal power of biosensors into the hands of those who need it



Universal Biosensors

Vet Diabetes Opportunity



Vet blood glucose monitoring market is growing

- Market growth is being driven by the increase of obesity in pets worldwide. This is causing an increase of chronic diseases which demand effective diagnostics.

Current market leaders not focused on new development

- Market leaders such as Zoetis Inc are not focused on new developments. Their leading monitoring product the AlphaTRAK 2 has not been updated for nearly 10 years.

Room for a new product to disrupt the market

- The AlphaTRAK 2 and CentriVet GK products dominate the market for vet blood glucose monitoring devices. There is an opportunity to win large market share for a superior device that is price competitive.

Bringing the universal power of biosensors into the hands of those who need it



Universal Biosensors


Vet Diabetes Large & Growing Market

Market is predicted to grow at a CAGR of 11.35% and be worth \$372 million AUD in 2026.

Major growth factors include:

- Increasing trend of pet adoption across the world.
- Owners are more concerned about their pet's health.
- Obesity in pets is increasing worldwide. 56% of dogs were recorded as obese in US in 2017.

Vet Blood Glucose Monitoring (Million AUD)




Vet Diabetes Product Launch

Much of the required technology is already owned and known to UBI.

No significant regulatory hurdles.

Target product launch H1 2022.



Xprecia Stride™

The Xprecia Stride Coagulation Analyser is a handheld device that reports PT/INR levels at the point of care with laboratory accuracy, for patients taking Warfarin.

Xprecia Stride has been sold by Siemens Healthineers since December 2014.

In 2019, UBI bought back the global distribution rights.

There is an installed base of over 3,500 units throughout the world.

Xprecia Stride is **sold in 36 countries**.

UBI's next generation PT-INR Coagulation Analyser is currently in development.



Xprecia Stride



Growing Market

Growing anticoagulation market worldwide.

Testing Market Decentralized

Shift of coagulation testing from laboratory setting to Point of Care devices in hospital, clinics and at home. The adoption of PT-INR home-testing is encouraged by the CMS reimbursement in the USA.

Next Gen Device

Work on Next Gen PT/INR Analyser has been finalised. This device will rival the Roche CoaguChek Plus's features and performance and retail at a lower price. The Regulatory Program (including clinical strategy) has begun. Launch expected 2022.

Bringing the universal power of biosensors into the hands of those who need it



Universal Biosensors

Xprecia Stride Next Gen Competitive Advantage

| | UBI: Next Gen | iLine: MicroINR | Roche: CoaguChek Vantus | Roche: CoaguChek Plus |
|--------------------|--------------------------|----------------------------|------------------------------------|----------------------------------|
| FDA Reg Status | PRO, PST, CLIA | PRO, PST, CLIA | PST | PRO, PST, CLIA |
| Sample Size (µL) | 8 | 3 | 8 | 8 |
| Unit of Measure | INR & SEC | INR | INR | INR, SEC %Q |
| Measuring Range | 0.8 – 8.0 | 0.8 – 6.0 | 0.8 – 6.0 | 0.8 – 8.0 |
| Touchscreen | Y | N | N | Y |
| Data Communication | Wired / Wireless | Wired | Wired / Wireless | Wireless |
| Power | Rechargeable | Rechargeable | 4 AAA Batteries | Rechargeable |
| Test Memory | 2000 | 199 | 400 | 2000 |
| Price | << \$650 | \$650 | \$650 - \$900 | \$1050 - \$1550 |

All prices are Australian dollars


Bringing the universal power of biosensors into the hands of those who need it



Universal Biosensors

Xprecia Stride PT-INR Market & Next Gen Timeline

| PT-INR | | | | |
|--------------------------------|------------|------------|------------|--------------|
| Global Market | USA | EU | ROW | Total |
| (AUD \$Million) | | | | |
| Total Hospital POC PT-INR | 223 | 168 | 63 | 454 |
| Total Doctor Office POC PT-INR | 151 | 113 | 42 | 306 |
| Total Home-Testing PT-INR | 179 | 106 | 40 | 325 |
| Total POC PT-INR | 553 | 387 | 145 | 1,085 |



Bringing the universal power of biosensors into the hands of those who need it



Universal Biosensors


Future of UBI

Move away from defining ourselves as an R&D company with long lead times and expensive research programs.

Purchase, license and partner new and complete biosensors.

Purchase, license and partner new technology to increase our detection limit.

Build a multi product stable of biosensors in large markets which generate revenue.



Bringing the universal power of biosensors into the hands of those who need it

Expanding our Vision

UBI is currently performing due diligence on a number of separate technology opportunities.

Each technology has the capability to increase the detection limits for our existing platform technology from Micromolar to Picomolar or better.

The successful development of any one of these technologies should materially expand the product range of UBI's existing platform technology into oncology, women's health, environmental impurities and other areas.

Bringing the universal power of biosensors into the hands of those who need it



**1 million tonne is
Base detection**



**1 tonne is a
million times smaller
(Micromolar)**




**1 gram is a
million times smaller
(Picomolar)**



Universal Biosensors

Why are Detection Limits Important



Bringing the universal power of biosensors into the hands of those who need it

END

John Sharman
Chief Executive Officer
Universal Biosensors, Inc

